---
schema_version: "secwatch.filing_event.v1"
accession: "0001827635-26-000010"
form_type: "8-K"
ticker: "MANE"
cik: "0001827635"
company_name: "Veradermics, Inc"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:25:55.415471+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled

## Summary
- FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.
- Cash, equivalents & marketable securities $141.9M at Dec 31, 2025; upsized IPO added $294.8M gross in Feb 2026.
- R&D expenses FY 2025 $62.1M (up $38.8M YoY) driven by VDPHL01 clinical development and headcount.
- Enrollment completed in Phase 2/3 Study 302 (male PHL) and confirmatory Study 304; topline data 1H and 2H 2026.
- Appointed Mark Neumann as Chief Commercial & Strategy Officer; Study 306 enrolling for female PHL.

## SEC filing metadata
- accession: 0001827635-26-000010
- form_type: 8-K
- ticker: MANE
- cik: 0001827635
- company_name: Veradermics, Inc
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/0001827635-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/mane-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827635-26-000010
- JSON: https://secwatch.observer/filing/0001827635-26-000010.json
- Plain text: https://secwatch.observer/filing/0001827635-26-000010.txt

## Key facts
- Earnings Releases
  Veradermics, Inc reported financial results for the fourth quarter and year ended December 31, 2025.
  - Period: the fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/0001827635-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.